Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820073 | 0.82 | PARP1 (0.38) | PARP1GABRA1GABRB2LOXL2ALOX5AP | |
| SCHEMBL24170711 | 0.81 | ELANE (0.40) | ELANEPARP1LOXL2 | |
| SCHEMBL28166591 | 0.81 | ELANE (0.46) | ELANEPARP1LOXL2 | |
| SCHEMBL25820084 | 0.80 | ALOX5AP (0.37) | GABRA1GABRB2LOXL2ALOX5AP | |
| SCHEMBL8404515 | 0.76 | ELANE (0.50) | ELANEPARP1 | |
| SCHEMBL2494065 | 0.75 | LOXL2 (0.58) | ELANELOXL2 | |
| SCHEMBL23371782 | 0.74 | ELANE (0.46) | ELANEPARP1GABRA1GABRB2LOXL2 | |
| SCHEMBL827170 | 0.74 | ELANE (0.42) | ELANEPARP1GABRA1GABRB2CTRB1 | |
| SCHEMBL25820134 | 0.73 | HTR1A (0.53) | PARP1GABRA1GABRB2 | |
| SCHEMBL14010021 | 0.72 | LOXL2 (0.38) | GABRA1GABRB2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ELANE 1623/4885PARP1 2894/4885GABRA1 3307/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ELANE 2543/4885PARP1 2205/4885GABRA1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.